Home Cart Sign in  
Chemical Structure| 21462-39-5 Chemical Structure| 21462-39-5

Structure of Clindamycin HCl
CAS No.: 21462-39-5

Chemical Structure| 21462-39-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Clindamycin HCl is an antibiotic useful for the treatment of a number of bacterial infections, largely replaced lincomycin due to an improved side effect profile.

Synonyms: Clindamycin hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Clindamycin HCl

CAS No. :21462-39-5
Formula : C18H34Cl2N2O5S
M.W : 461.44
SMILES Code : O=C([C@H]1N(C)C[C@H](CCC)C1)N[C@@H]([C@]2([H])[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O2)[C@@H](Cl)C.[H]Cl
Synonyms :
Clindamycin hydrochloride
MDL No. :MFCD07793327
InChI Key :AUODDLQVRAJAJM-XJQDNNTCSA-N
Pubchem ID :16051951

Safety of Clindamycin HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical vein endothelial cells 30-1000 μg/ml 24, 48, 72, 120 h To evaluate the effects of clindamycin on the proliferation, toxicity, and angiogenic potential of human umbilical vein endothelial cells. Results showed that clindamycin at lower concentrations (30 and 50 μg/ml) enhanced angiogenic potential, similar to VEGF; but significantly reduced cell proliferation and angiogenic potential at higher concentrations (100 μg/ml and above). J Endod. 2019 Jul;45(7):882-889
Dental pulp stem cells 30-1000 μg/ml 24, 48, 72, 120 h To evaluate the effects of clindamycin on the proliferation and toxicity of dental pulp stem cells. Results showed that clindamycin at lower concentrations (30 and 50 μg/ml) had no significant effect on cell proliferation, but significantly reduced proliferation at higher concentrations (250 μg/ml and above). J Endod. 2019 Jul;45(7):882-889
Plasmodium falciparum CamWT_C580Y 25.6 nM (IC50) 144 h To evaluate the in vitro inhibitory effect of clindamycin on drug-resistant malaria parasites, showing an IC50 of 25.6 nM. Int J Parasitol Drugs Drug Resist. 2025 Apr;27:100577
Plasmodium falciparum CamWT 19.5 nM (IC50) 144 h To evaluate the in vitro inhibitory effect of clindamycin on malaria parasites, showing an IC50 of 19.5 nM. Int J Parasitol Drugs Drug Resist. 2025 Apr;27:100577
Inducible clindamycin-resistant Staphylococcus aureus strains 1/2 MIC, 1/4 MIC, 1/8 MIC 6 h To investigate the effect of clindamycin at sub-inhibitory concentrations on virulence factor expression in inducible clindamycin-resistant S. aureus strains. Results showed that clindamycin significantly decreased the expression of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1), and alpha-haemolysin (Hla). Ann Clin Microbiol Antimicrob. 2018 Oct 20;17(1):38

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Neutropenic mouse thigh infection model Intraperitoneal injection 150 mg/kg Every 8 hours for 72 hours Evaluate the in vivo activity of clindamycin against inducibly resistant beta-hemolytic streptococci. Results showed regrowth of inducibly resistant strains by 48 h, similar to constitutively resistant isolates. Antimicrob Agents Chemother. 2014;58(3):1327-31
Golden Syrian hamsters PPA-induced neurotoxicity model Oral 30 mg/kg Single dose To evaluate the effect of clindamycin on neurotoxicity, results showed that clindamycin-treated hamsters had significantly increased levels of proapoptotic markers (CASP 3 and 7) and stress-induced protein HSP70 in the brain. Food Sci Nutr. 2021 Jul 13;9(9):4874-4882
Pigs Adult pig models Oral 50 mg/kg 1 day To study the effect of Clindamycin on the gut microbiome of pigs and its impact on Clostridium difficile infection. Results showed that Clindamycin treatment caused significant shifts in the fecal microbiome, decreased microbial diversity, and significantly increased body temperature. Fecal shedding of C. difficile was detectable for 9 days in Clindamycin-treated pigs inoculated with C. difficile. Front Cell Infect Microbiol. 2019 Aug 6;9:271
Mice Plasmodium berghei GFP-luciferase low and high parasitemia model Intraperitoneal injection 25 mg/kg or 100 mg/kg Every 6 or 12 hours for 2 to 4.5 days To evaluate the antimalarial efficacy of clindamycin under different dosing frequencies, showing that more frequent dosing (every 6 hours) was more effective than a single large dose. Int J Parasitol Drugs Drug Resist. 2025 Apr;27:100577

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.84mL

2.17mL

1.08mL

21.67mL

4.33mL

2.17mL

References

 

Historical Records

Categories